Pacira Biosciences
PCRX
#5897
Rank
ยฃ0.64 B
Marketcap
ยฃ13.96
Share price
0.60%
Change (1 day)
-34.33%
Change (1 year)
Categories

P/E ratio for Pacira Biosciences (PCRX)

P/E ratio as of November 2024 (TTM): 124

According to Pacira Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 124.143. At the end of 2022 the company had a P/E ratio of 110.

P/E ratio history for Pacira Biosciences from 2011 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202211074.17%
202163.3257.75%
202017.7-110.55%
2019-168-92.2%
2018< -10005036.01%
2017-41.930.96%
2016-32.0-101.67%
2015> 1000-961.4%
2014-222644.1%
2013-29.8194.98%
2012-10.1225.71%
2011-3.10

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-2.79-102.24%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
-0.1505-100.12%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.9060-100.73%๐Ÿ‡บ๐Ÿ‡ธ USA
12.1-90.27%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.56-105.28%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.